The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-12-04
DOI
10.3389/fonc.2020.569202
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
- (2020) Huiping Qiang et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- A signature of tumor immune microenvironment genes associated with the prognosis of non‑small cell lung cancer
- (2020) Jia Li et al. ONCOLOGY REPORTS
- Comprehensive T cell repertoire characterization of non-small cell lung cancer
- (2020) Alexandre Reuben et al. Nature Communications
- Inter-tumor heterogeneity of PD-L1 expression in non-small cell lung cancer
- (2020) Yuichi Saito et al. Journal of Thoracic Disease
- Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer
- (2020) Lingzhi Hong et al. Journal of Thoracic Oncology
- Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
- (2020) Nayoung Kim et al. Nature Communications
- Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors
- (2020) Lara Gibellini et al. Frontiers in Immunology
- Tumor mutational burden (TMB) standardization initiatives: Recommendations for consistent TMB assessment in clinical samples to guide immunotherapy treatment decisions
- (2019) Albrecht Stenzinger et al. GENES CHROMOSOMES & CANCER
- Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
- (2019) Jérôme Galon et al. NATURE REVIEWS DRUG DISCOVERY
- Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
- (2019) Léa Berland et al. Journal of Thoracic Disease
- PD-L1 Expression in Circulating Tumor Cells Increases during Radio(chemo)therapy and Indicates Poor Prognosis in Non-small Cell Lung Cancer
- (2019) Yang Wang et al. Scientific Reports
- Neoantigen-directed immune escape in lung cancer evolution
- (2019) Rachel Rosenthal et al. NATURE
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
- (2019) Tuba N. Gide et al. CANCER CELL
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy
- (2019) Heng-Huan Lee et al. CANCER CELL
- Tumor mutation burden: from comprehensive mutational screening to the clinic
- (2019) Francesca Galuppini et al. Cancer Cell International
- Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape
- (2019) Arsen Osipov et al. Journal for ImmunoTherapy of Cancer
- Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer
- (2019) Kroopa Joshi et al. NATURE MEDICINE
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer
- (2018) A. Pabani et al. Current Oncology
- Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments
- (2018) Shota Omori et al. International Journal of Clinical Oncology
- Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer
- (2018) Won-Chul Lee et al. MODERN PATHOLOGY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand–1 Expression for Immunotherapy in Non–Small Cell Lung Cancer
- (2018) Emily B. Tsai et al. RADIOLOGY
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches
- (2018) Edwin R. Parra et al. Journal for ImmunoTherapy of Cancer
- Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis
- (2018) Ivo Buchhalter et al. INTERNATIONAL JOURNAL OF CANCER
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
- (2018) Yu Yu et al. Oncology Letters
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- The 2018 Nobel Prize in medicine goes to cancer immunotherapy
- (2018) Zong Sheng Guo BMC CANCER
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
- (2017) Alexa B. Schrock et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
- (2017) Samra Turajlic et al. LANCET ONCOLOGY
- Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
- (2017) Thomas J Gniadek et al. MODERN PATHOLOGY
- PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer
- (2017) Katerina Ancevski Hunter et al. Molecular Diagnosis & Therapy
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- (2017) Mariam Jamal-Hanjani et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes
- (2017) Paweł Krawczyk et al. Oncotarget
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
- (2016) A. S. Mansfield et al. ANNALS OF ONCOLOGY
- Non–Small Cell Lung Cancer, PD-L1, and the Pathologist
- (2016) Keith M. Kerr et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Programmed Death Ligand-1 Immunohistochemistry— A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society
- (2016) Lynette M. Sholl et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy for lung cancer
- (2016) Antonius Steven et al. RESPIROLOGY
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
- (2016) Chia-Wei Li et al. Nature Communications
- The role of tumor microenvironment in therapeutic resistance
- (2016) Beomseok Son et al. Oncotarget
- The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine
- (2016) Andrea Garofalo et al. Genome Medicine
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
- (2016) Joseph McLaughlin et al. JAMA Oncology
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
- (2015) M. Ilie et al. ANNALS OF ONCOLOGY
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- (2015) Nicholas McGranahan et al. CANCER CELL
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- Spatial Heterogeneity in Drug Concentrations Can Facilitate the Emergence of Resistance to Cancer Therapy
- (2015) Feng Fu et al. PLoS Computational Biology
- Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine
- (2014) Eliezer M Van Allen et al. NATURE MEDICINE
- Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
- (2014) J. Zhang et al. SCIENCE
- From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
- (2013) Helen Angell et al. CURRENT OPINION IN IMMUNOLOGY
- The tumor microenvironment at a glance
- (2013) F. R. Balkwill et al. JOURNAL OF CELL SCIENCE
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
- (2013) Jérôme Galon et al. JOURNAL OF PATHOLOGY
- Influence of tumour micro-environment heterogeneity on therapeutic response
- (2013) Melissa R. Junttila et al. NATURE
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Tumor Microenvironment Complexity: Emerging Roles in Cancer Therapy
- (2012) M. A. Swartz et al. CANCER RESEARCH
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
- (2010) A. McKenna et al. GENOME RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started